Curcumin Nanodelivery for Tumor-Associated Macrophage Reprogramming and Immune-Checkpoint Sensitization: Engineering the Tumor Immune Microenvironment

Background/Objectives: Curcumin possesses antineoplastic and immunomodulatory activities. However, poor aqueous solubility, chemical instability, rapid conjugative metabolism, and limited systemic exposure restrict meaningful concentrations within tumors. Numerous reviews have already addressed curcumin nanoformulations, improved bioavailability, and general anticancer effects. However, delivery architecture, cell-specific curcumin exposure, TAM functional reprogramming, macrophage–lymphocyte crosstalk, and checkpoint response remain insufficiently integrated. This review connects these components while distinguishing experimentally demonstrated links from mechanistic inference and examines whether engineered curcumin nanodelivery can remodel TAM-associated biology to improve responsiveness to PD-1/PD-L1-directed therapy. Methods: A structured narrative review was conducted using experimental studies of curcumin delivery, macrophage targeting and reprogramming, intracellular signaling, macrophage–lymphocyte crosstalk, and checkpoint regulation. Results: Evidence supports curcumin-associated modulation of STAT3/STAT6, PI3K–AKT, context-dependent NF-κB, HIF-1α, redox, and metabolic pathways, accompanied by reduced immunosuppressive mediators and enhanced antitumor macrophage functions. Emerging nanoplatforms further report TAM remodeling, immunogenic cell death, enhanced T-cell responses, and additional therapeutic benefit in checkpoint-containing regimens. However, these endpoints are usually distributed across different experimental systems rather than one complete causal sequence. We therefore distinguish validated TAM targeting from tumor accumulation, biomimetic tumor homing, secondary TAM exposure, and combination benefit from demonstrated checkpoint sensitization. Conclusions: We propose a multidimensional D1–D8 evidence framework evaluating pharmaceutical performance, tumor exposure, TAM-specific uptake and intracellular parent curcumin, pathway modulation, functional TAM reprogramming, downstream immune restoration, checkpoint-therapy response, and translational relevance as independent domains. This prevents efficacy in one domain from being interpreted as proof of unmeasured links elsewhere and advances cell-resolved, mechanism-driven curcumin immunonanomedicine.